The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

AstraZeneca's three-drug inhaler Breztri has shown efficacy for uncontrolled asthma in a pair of trials that could extend its label beyond COPD. Market Access Sponsored ...

The Company History page lists out the major events in chronological order for AstraZeneca Pharma India Ltd. Company History - AstraZeneca Pharma India Ltd.